Clinical Edge Journal Scan

Risk for atopic dermatitis in children alters with the mode of delivery


 

Key clinical point: Children born by cesarean section or instrumental vaginal delivery are at a greater risk of developing atopic dermatitis (AD) compared with those born by uncomplicated vaginal delivery.

Major finding: Children aged <1 year born by instrumental vaginal delivery (adjusted hazard ratio [aHR] 1.10; 95% CI 1.07-1.13 ), emergency cesarean section (aHR 1.12; 95% CI 1.10-1.15 ), and elective caesarean section (aHR 1.13; 95% CI 1.10-1.16 ) were at a higher risk for AD compared with those born by uncomplicated vaginal delivery, with the risk being similar in children aged ≥1 year.

Study details: This prospective population-based study included 1,399,406 children aged ≤5 years with available information on the mode of delivery and mother's identity .

Disclosures: This study was supported by the Swedish Research Council, Swedish Heart-Lung Foundation, and Stiftelsen Frimurare Barnhuset i Stockholm. The authors declared no conflicts of interest.

Source: Mubanga M et al. Mode of delivery and offspring atopic dermatitis in a Swedish nationwide study. Pediatr Allergy Immunol. 2023;34(1):e13904 (Jan 11). Doi: 10.1111/pai.13904

Recommended Reading

Long-term integrated safety of baricitinib in moderate-to-severe atopic dermatitis
MDedge Dermatology
Upadacitinib is effective in treating difficult-to-treat moderate-to-severe atopic dermatitis
MDedge Dermatology
Prolonged dupilumab therapy is safe and effective in moderate-to-severe atopic dermatitis
MDedge Dermatology
Childhood atopic dermatitis is associated with increased fatigue
MDedge Dermatology
Atopic dermatitis: No association between dupilumab use and malignancy
MDedge Dermatology
Atopic dermatitis is positively linked with the risk for juvenile idiopathic arthritis
MDedge Dermatology
Meta-analysis reveals that most atopic dermatitis therapies are effective against pruritus
MDedge Dermatology
Commentary: A New Drug, and Pediatric Concerns, February 2023
MDedge Dermatology
FDA expands oral JAK abrocitinib to adolescents with AD
MDedge Dermatology
Dupilumab shows rapid and sustained efficacy and favorable safety in erythrodermic atopic dermatitis
MDedge Dermatology